|
IUPAC name | (3β)-3-[(3-carboxypropanoyl)oxy]-11-oxoolean-12-en-30-oic acid OR (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-(3-carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid | Mol. mass | 570.765 g/mol |
|
Carbenoxolone, a synthetic derivative of glycyrrhetinic acid, is a licensed drug (in the UK) for oesophageal ulceration and inflammation. Other uses include treatment of oral and perioral lesions.
Carbenoxolone (aka Carbenoxolone, CBX) is also used as a blocker of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD), of pannexon membrane channels (comprising 6 subunits of pannexin) and the related innexon channels (consisting of invertebrate innexins), and at higher concentrations, as a blocker of connexon channels ("hemichannels" made up of 6 connexin subunits each) and of gap junctions (2 connexons joined together).
|
|
|